FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2012509110> ?p ?o ?g. }

• W2012509110 endingPage "145" @default.
• W2012509110 startingPage "126" @default.
• W2012509110 abstract "Understanding the intermolecular products of antibodies as a consequence of host-cell expression, aging, and heat-stress can be insightful especially when it involves the development of a stable biopharmaceutical product. The dimerized form of Epratuzumab (an IgG1 antibody) with a molecular mass of ∼300 kDa (twice the monomer antibody molecular weight of ∼150 kDa) was examined to gain a better perspective of its properties pertaining to structure and activity. The nascent dimer was shown to partially dissociate upon incubation at 30°C and 37°C, exhibit no discernable alteration of structure (i.e., secondary or tertiary structure based on CD and 2nd derivative UV spectroscopy), have ∼70% covalent forms (based upon CE-SDS results) and manifest twofold higher activity relative to the active monomer form (on a weight basis the dimer and monomer have equal activity). Interestingly, these properties were not attributed to a single dimer species, but rather to a more complex dimer assembly. The Epratuzumab dimer was digested with papain to reveal three uniquely dimerized aggregates. The relative molar distribution of Fab:Fab, Fc:Fc, and Fab:Fc was found to be 4:3:8, respectively. The data suggest that all three predominantly covalent dimer adducts are capable of full activity, shedding light on their complex nature and showing that their target specificity was unaltered. ESI-MS data indicated the presence of remnant levels of noncovalent dimers for all three dimerized forms. Material aged at 37°C exhibited a similar papain digest molar distribution of the three dimerized forms, except with enhanced chemical heterogeneity and an increase in covalent forms to ∼84%. © 2005 Wiley-Liss, Inc. and the American Pharmacists Association Understanding the intermolecular products of antibodies as a consequence of host-cell expression, aging, and heat-stress can be insightful especially when it involves the development of a stable biopharmaceutical product. The dimerized form of Epratuzumab (an IgG1 antibody) with a molecular mass of ∼300 kDa (twice the monomer antibody molecular weight of ∼150 kDa) was examined to gain a better perspective of its properties pertaining to structure and activity. The nascent dimer was shown to partially dissociate upon incubation at 30°C and 37°C, exhibit no discernable alteration of structure (i.e., secondary or tertiary structure based on CD and 2nd derivative UV spectroscopy), have ∼70% covalent forms (based upon CE-SDS results) and manifest twofold higher activity relative to the active monomer form (on a weight basis the dimer and monomer have equal activity). Interestingly, these properties were not attributed to a single dimer species, but rather to a more complex dimer assembly. The Epratuzumab dimer was digested with papain to reveal three uniquely dimerized aggregates. The relative molar distribution of Fab:Fab, Fc:Fc, and Fab:Fc was found to be 4:3:8, respectively. The data suggest that all three predominantly covalent dimer adducts are capable of full activity, shedding light on their complex nature and showing that their target specificity was unaltered. ESI-MS data indicated the presence of remnant levels of noncovalent dimers for all three dimerized forms. Material aged at 37°C exhibited a similar papain digest molar distribution of the three dimerized forms, except with enhanced chemical heterogeneity and an increase in covalent forms to ∼84%. © 2005 Wiley-Liss, Inc. and the American Pharmacists Association" @default.
• W2012509110 created "2016-06-24" @default.
• W2012509110 creator A5002476539 @default.
• W2012509110 creator A5007060207 @default.
• W2012509110 creator A5008773268 @default.
• W2012509110 creator A5011149614 @default.
• W2012509110 creator A5026527473 @default.
• W2012509110 creator A5036374218 @default.
• W2012509110 creator A5043001825 @default.
• W2012509110 creator A5050678105 @default.
• W2012509110 creator A5051780803 @default.
• W2012509110 creator A5054717596 @default.
• W2012509110 creator A5064333126 @default.
• W2012509110 creator A5083898471 @default.
• W2012509110 date "2006-01-01" @default.
• W2012509110 modified "2023-10-17" @default.
• W2012509110 title "Active dimer of Epratuzumab provides insight into the complex nature of an antibody aggregate" @default.
• W2012509110 cites W1493053489 @default.
• W2012509110 cites W1497904783 @default.
• W2012509110 cites W1521861424 @default.
• W2012509110 cites W1527693100 @default.
• W2012509110 cites W1600203168 @default.
• W2012509110 cites W1961446843 @default.
• W2012509110 cites W1964126053 @default.
• W2012509110 cites W1968280815 @default.
• W2012509110 cites W1981417623 @default.
• W2012509110 cites W1986890848 @default.
• W2012509110 cites W1992476540 @default.
• W2012509110 cites W1993463598 @default.
• W2012509110 cites W1995896973 @default.
• W2012509110 cites W2002328341 @default.
• W2012509110 cites W2006903449 @default.
• W2012509110 cites W2008462417 @default.
• W2012509110 cites W2010216657 @default.
• W2012509110 cites W2016994355 @default.
• W2012509110 cites W2026311677 @default.
• W2012509110 cites W203450371 @default.
• W2012509110 cites W2041588298 @default.
• W2012509110 cites W2048427986 @default.
• W2012509110 cites W2056295648 @default.
• W2012509110 cites W2059435741 @default.
• W2012509110 cites W2060588671 @default.
• W2012509110 cites W2064406098 @default.
• W2012509110 cites W2069775769 @default.
• W2012509110 cites W2069848747 @default.
• W2012509110 cites W2073292063 @default.
• W2012509110 cites W2079912248 @default.
• W2012509110 cites W2081658214 @default.
• W2012509110 cites W2082675740 @default.
• W2012509110 cites W2083423150 @default.
• W2012509110 cites W2088940572 @default.
• W2012509110 cites W2092562610 @default.
• W2012509110 cites W2100861268 @default.
• W2012509110 cites W2133101605 @default.
• W2012509110 cites W2141654481 @default.
• W2012509110 cites W2153701071 @default.
• W2012509110 cites W2157595073 @default.
• W2012509110 cites W2167182434 @default.
• W2012509110 cites W2329952272 @default.
• W2012509110 cites W2505652147 @default.
• W2012509110 cites W58904424 @default.
• W2012509110 doi "https://doi.org/10.1002/jps.20515" @default.
• W2012509110 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16315222" @default.
• W2012509110 hasPublicationYear "2006" @default.
• W2012509110 type Work @default.
• W2012509110 sameAs 2012509110 @default.
• W2012509110 citedByCount "60" @default.
• W2012509110 countsByYear W20125091102012 @default.
• W2012509110 countsByYear W20125091102013 @default.
• W2012509110 countsByYear W20125091102014 @default.
• W2012509110 countsByYear W20125091102015 @default.
• W2012509110 countsByYear W20125091102016 @default.
• W2012509110 countsByYear W20125091102017 @default.
• W2012509110 countsByYear W20125091102018 @default.
• W2012509110 countsByYear W20125091102019 @default.
• W2012509110 countsByYear W20125091102020 @default.
• W2012509110 countsByYear W20125091102021 @default.
• W2012509110 countsByYear W20125091102023 @default.
• W2012509110 crossrefType "journal-article" @default.
• W2012509110 hasAuthorship W2012509110A5002476539 @default.
• W2012509110 hasAuthorship W2012509110A5007060207 @default.
• W2012509110 hasAuthorship W2012509110A5008773268 @default.
• W2012509110 hasAuthorship W2012509110A5011149614 @default.
• W2012509110 hasAuthorship W2012509110A5026527473 @default.
• W2012509110 hasAuthorship W2012509110A5036374218 @default.
• W2012509110 hasAuthorship W2012509110A5043001825 @default.
• W2012509110 hasAuthorship W2012509110A5050678105 @default.
• W2012509110 hasAuthorship W2012509110A5051780803 @default.
• W2012509110 hasAuthorship W2012509110A5054717596 @default.
• W2012509110 hasAuthorship W2012509110A5064333126 @default.
• W2012509110 hasAuthorship W2012509110A5083898471 @default.
• W2012509110 hasConcept C12554922 @default.
• W2012509110 hasConcept C133571119 @default.
• W2012509110 hasConcept C166940927 @default.
• W2012509110 hasConcept C166950319 @default.
• W2012509110 hasConcept C178790620 @default.
• W2012509110 hasConcept C180577832 @default.
• W2012509110 hasConcept C181199279 @default.

• next